Αρχική World News Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical...

Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma

Overall survival (OS) was significantly improved with cemiplimab as compared to investigator’s choice of chemotherapy in patients with recurrent/metastatic cervical cancer and progression after first-line platinum-based treatment, according to interim findings from a phase III study presented at the ESMO Virtual Plenaries (12 & 13 May 2021).

Krishnansu Sujata Tewari of the Obstetrics & Gynaecology Department, UC Irvine Medical Centre in Orange, CA, USA presented interim results on behalf of co-investigators from the open-label, randomised, multicentre, phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study (NCT03257267). He explained that salvage chemotherapy has been shown to be ineffective in patients with recurrent/metastatic cervical cancer following progression on first-line platinum-based chemotherapy with or without bevacizumab, thus prompting this evaluation of the anti-PD1 agent cemiplimab.

The study compared cemiplimab with investigator’s choice of single agent chemotherapy in patients with recurrent/metastatic cervical cancer that progressed after first-line platinum-based treatment.

Enrollment was regardless of PD-L1 expression. Following 1:1 randomisation 304 patients were treated with cemiplimab at 350 mg per i.v. every 3 weeks and 304 received investigator’s choice of chemotherapy comprised of either pemetrexed, vinorelbine, gemcitabine, irinotecan, or topotecan for up to 96 weeks. The patients were stratified by histology (squamous cell carcinoma [SCC; n=477] / adenocarcinoma or adenosquamous [AC; n=131]). The patients’ median age was 51 years (range, 22 to 87) and the ECOG performance score 0 in 46.5% and 1 in 53.5% of patients.

The primary endpoint was OS, which was analysed hierarchically in patients with SCC followed by the total population of patients. Progression-free survival (PFS), objective response rate (ORR), quality of life (QoL) and safety served as additional endpoints. The interim analysis was scheduled when 85% events had occurred among patients with SCC.

The median exposure to cemiplimab was 15 weeks (range, 1.4 to 100.7).

Statistically significant OS improvements were observed across both histologies and in the overall population

The interim analysis demonstrated that all endpoints evaluated favoured cemiplimab in the overall and SCC patient population, including OS, PFS, ORR, and mean change in QoL from baseline in the SCC patients.

Regarding the primary endpoint, median OS in the total population was 12.0 months with cemiplimab compared to 8.5 months with chemotherapy (hazard ratio [HR] 0.69;
95% confidence interval [CI] 0.56‒0.84; p < 0.001).

Among 239 SCC patients on cemplimab, median OS was 11.1 months compared to 8.8 months in 238 SCC patients receiving chemotherapy (HR 0.73; 95% CI 0.58‒0.91; p = 0.003).

In the AC population, the 65 patients receiving cemplimab demonstrated median OS of 13.3 months compared to 7.0 months in the 66 patients receiving chemotherapy (HR 0.56; 95% CI 0.36‒0.85; p < 0.005 nominal p value, not adjusted for multiplicity).

Treatment emergent adverse events (TEAEs) were lower with cemplimab versus chemotherapy; the most commonly reported TEAEs of any grade were anaemia (25% versus 45%), nausea (18% versus 33%), and vomiting (16% versus 23%), respectively.

Eight percent of patients treated with cemplimab discontinued due to AEs versus 5% of patients on investigator’s choice of chemotherapy.  


Based on these interim findings, the authors were able to conclude that cemiplimab significantly improves OS over single agent chemotherapy in patients with recurrent/metastatic cervical cancer with progression following first-line platinum-based therapy. Furthermore, cemiplimab activity was regardless of PD-L1 status or histology. According to the authors, no new safety signals were observed.

The study was funded by Regeneron Pharmaceuticals, Inc. and Sanofi.


Tewari KS, Monk BJ, Vergote I, et al. EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase 3 trial of cemiplimab vs investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic /R/M) cervical carcinoma. ESMO Virtual Plenaries (12 & 13 May 2021).


Προηγούμενο άρθροExpressive Writing, What is It?
Επόμενο άρθροOvarian cancer screening trial did not save lives


Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

SABCS 2021: New Research and Updates in Breast Cancer Treatment and Side Effects

The 2021 San Antonio Breast Cancer Symposium (SABCS) was held from December 7 to 10 in San Antonio, Texas, and online. In this podcast,...

Cancer Research UK publishes gender and ethnicity pay gap reports

As part of Cancer Research UK’s ongoing commitment to improving the diversity of the organisation, the charity has today published its gender pay gap...

Can mRNA Vaccines Help Treat Cancer?

January 20, 2022, by NCI Staff A technician working on mRNA vaccine production. Credit: Image used with permission from BioNTech The coronavirus pandemic has thrown a spotlight...

A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma

COMBI-i did not show a statistically significant difference in investigator-assessed progression-free survival (PFS) in the broad population of patients with BRAF V600–mutated metastatic melanoma treated in...

Wawa Employee Saves Life Of Customer Who Stopped Breathing After A Seizure

When 19-year-old John Wallop arrived for his 16-hour shift behind the deli counter at Wawa in Millville, New Jersey, he thought it would just...

New breast and lung cancer treatments approved in Scotland

A breast cancer cell 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland,...